Pacira BioSciences, Inc.
NASDAQ:PCRXDrug Manufacturers - Specialty & Generic
-$0.18 today
- Market cap
- $1.46B
- Beta
- 0.29
- P/E (TTM)
- 176.9
- EPS (TTM)
- $0.13
Volume 1.81M
Average 0.57M
PCRX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Pacira BioSciences, Inc.NASDAQ: PCRX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $136.34M rose 2.8% year over year, ahead of the -11.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Operating expenses amounted to 74.8% of revenue in FY2025, down 11.4 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2.8% holds above the trailing-twelve-month pace of -11.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 543.36M USD
- Year-over-year change
- -10.0%
- 4-year CAGR
- +14.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 543.36M | -10.0% |
| FY2024 | 2024-12-31 | 603.91M | +50.0% |
| FY2023 | 2023-12-31 | 402.63M | -1.2% |
| FY2022 | 2022-12-31 | 407.5M | +30.9% |
| FY2021 | 2021-12-31 | 311.35M | — |
Operating Expenses vs competitors
How PCRX compares with its peers on the latest reported figures
- PCRX's LTM Mar 2026 operating expenses of $560.33M is the 2nd highest of the 4 companies compared; the peer median is $295.28M.
- Its year-over-year change of -11.1% is the lowest of 4, against a peer median of +60.9%.
- Operating expenses amounts to 76.2% of revenue for PCRX, versus a peer median of 101.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $844.11M | +60.9% | +8.5% | 101.6% | |
| LTM Mar 2026 | $560.33M | -11.1% | +10.1% | 76.2% | |
| LTM Mar 2026 | $295.28M | +130.2% | +54.5% | 872.0% | |
| LTM Mar 2026 | $293.27M | +21.6% | +16.2% | 36.8% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PCRX) | $295.28M | +60.9% | +16.2% | 101.6% | |
Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 541.53M | 666.82M | 674.98M | 700.97M | 726.41M |
| Cost of Revenue | 140.26M | 199.3M | 184.67M | 170.43M | 149.75M |
| Gross Profit | 401.28M | 467.53M | 490.31M | 530.54M | 576.66M |
| Gross Margin | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| Research & Development | 55.55M | 84.8M | 76.26M | 81.58M | 117.31M |
| Selling, General & Admin | 199.35M | 254.52M | 269.44M | 294.1M | 368.76M |
| Operating Expenses | 311.35M | 407.5M | 402.63M | 603.91M | 543.36M |
| Depreciation & Amortization | 28.55M | 91.5M | 75.57M | 78.79M | 91.02M |
| EBITDA | 113.95M | 140.38M | 154.59M | 29.12M | 122.5M |
| EBITDA Margin | 21.0% | 21.1% | 22.9% | 4.2% | 16.9% |
| Operating Income | 89.92M | 60.02M | 87.68M | (73.37M) | 33.3M |
| Operating Margin | 16.6% | 9.0% | 13.0% | -10.5% | 4.6% |
| Interest Income | 896K | 4.54M | 11.44M | 19.69M | 22.73M |
| Interest Expense | 29M | 35.58M | 17.31M | 16.57M | 14.61M |
| Other Income / Expenses | (33.52M) | (46.72M) | (25.97M) | 10.27M | (16.43M) |
| Income Before Tax | 56.4M | 13.3M | 61.7M | (63.11M) | 16.87M |
| Pre-Tax Margin | 10.4% | 2.0% | 9.1% | -9.0% | 2.3% |
| Income Tax Expense | 14.42M | (2.61M) | 19.75M | 36.45M | 9.84M |
| Net Income | 41.98M | 15.91M | 41.96M | (99.56M) | 7.03M |
| Net Margin | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| EPS (Basic) | 0.95 | 0.35 | 0.91 | (2.15) | 0.16 |
| EPS (Diluted) | 0.92 | 0.34 | 0.89 | (2.15) | 0.16 |
| Weighted Avg Shares | 44.26M | 45.52M | 46.22M | 46.25M | 44.57M |
| Weighted Avg Shares (Diluted) | 45.63M | 46.54M | 51.98M | 46.25M | 45.04M |
Pacira BioSciences, Inc.
NASDAQ:PCRX
Intrinsic Alpha fair value
Locked
Current Price
$36.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.